Huma Therapeutics partners with Buyer to develop an assessment tool to determine an individual’s risk factors for CVD.

Author:  |  Published on: February 3, 2023  |  Last updated: February 3, 2023
Beacon Biosignals acquires Snap Diagnostics for home EEG sleep testing
October 26, 2026
Biograph finds coronary inflammation in 43% of asymptomatic adults
October 26, 2026
Whole-body MRI links sleep patterns with belly fat and brain volume
October 26, 2026
L-Nutra Health launches metabolic programme to UK clinics
October 23, 2026
NRG Therapeutics launches brain-tracking study for new neurodegenerative drug
October 23, 2026
Muna Therapeutics’ Alzheimer’s drug MNA-001 passes early safety trial
October 23, 2026
FDA clears NeuroXT’s AI software to assess Alzheimer’s progression risk
October 23, 2026
Immunis wins grand prize for novel anti-aging stem cell therapy
October 23, 2026
Cognition Therapeutics gets FDA alignment for Phase 3 Zervimesine trial
October 23, 2026
Fractyl shifts focus to Revita weight-maintenance procedure following successful trial
October 23, 2026
NeuroXT earns FDA clearance for AI brain scan analyzer for Alzheimer’s
October 22, 2026
Fountain Life named Longevity Clinic of the Year
October 22, 2026
Omada Health to present research on weight loss during GLP-1 therapy
October 21, 2026
Rivus to present data on new oral weight-loss drug that targets fat while saving muscle
October 21, 2026
FDA clears Phase 2 trial for United Therapeutics’ COPD lung disease treatment
October 21, 2026
Insilico reaches first milestone in Servier collaboration
October 21, 2026
Veradermics to discuss Phase 3 ‘304’ topline results on call
October 20, 2026
XellSmart reports Phase I Parkinson’s cell therapy data
October 20, 2026